Gate 0 defines the system conditions required before entering the sequenced intervention architecture. These preconditions ensure that Gates 1–6 act on a system that is stable enough to tolerate biofilm disruption, antimicrobial pressure, binding phases, and nutrient restoration. Gate 0 is not an intervention phase; it is an assessment and stabilization phase designed to prevent destabilizing interactions.
—
1. Overview
The ecological state documented in Part I—high Proteobacteria, collapsed anaerobic guilds, permeability >80, epithelial injury, bile-acid stress, immune activation, gastric acid impairment—creates a narrow therapeutic window.
Gate 0 establishes the baseline configuration required for controlled sequencing.
Gate 0 includes:
—
2. Eligibility and Risk Thresholds
Before initiating Gate 1, the following conditions should be met or evaluated:
2.1 Relative metabolic stability
The system must not be in an acute inflammatory flare, uncontrolled infection, or severe metabolic decompensation.
High inflammatory tone is expected, but destabilization from non-gut sources should be excluded so that shifts generated by the protocol can be interpreted.
2.2 No acute immunological crisis
Chronic activation—as seen in RA, MCAS-like symptoms, or persistent inflammatory markers—is compatible with Gate initiation.
Acute crises (e.g., severe allergic events) would distort early Gate responses.
2.3 Gastrointestinal baseline
Per Part I:
These findings must be stable enough to support controlled pressure from early Gates.
2.4 No ongoing destabilizing exposures
Iron infusions, NSAID overuse, acute antibiotics, or new immunomodulators can distort the ecological trajectories targeted in the Gates and must be absent during initiation.
—
3. Baseline Microbial and Laboratory Markers
Gate 0 documents the ecological starting point as a reference for later interpretation.
3.1 Microbial composition
August 2024 → September 2025:
These values establish that Gate 1 must operate on a system with extreme pathobiont dominance.
3.2 Functional scores
Thorne (2025):
These scores define the functional burdens that will shift through the sequencing process.
3.3 Barrier function
Markers and clinical presentation confirm a high-permeability state with epithelial stress and inadequate mucin protection.
3.4 Motility
Motility irregularities (“neuromotor electricity,” lower abdominal discomfort) were present but intermittent, indicating partial—but not complete—MMC disruption.
3.5 Gastric acid impairment
Clinical evaluation identified impaired HCl production, raising antigen load and microbial survival through the upper GI tract.
This is not remedied in the Gates directly but establishes a background constraint.
—
4. Initial System Constraints
Gate 0 identifies the constraints that shape the sequencing logic:
4.1 Biofilm protection
Biofilms shield Enterobacteriaceae-dominant communities.
Gate 1 relies on this being present so that disruption produces a measurable effect.
4.2 High luminal oxygen tension
Loss of anaerobic keystones means oxygen levels will be higher than normal.
Gate 2’s antimicrobial pressure relies on the disruption achieved by Gate 1.
4.3 Bile-acid instability
Primary bile-acid injury and incomplete enterohepatic cycling require binding phases later in the sequence.
4.4 Redox imbalance
Oxidative pressure and mitochondrial strain must be taken into account when designing Gate 4.
4.5 Absence of keystone anaerobes
Gate 6 is contingent on this absence; early restoration attempts would fail.
—
5. Guardrails and Cautions
Gate 0 documents specific boundary conditions to prevent mis-sequencing:
5.1 Avoiding premature introduction of fibers or SCFA substrates
Introducing fiber or high-fermentation substrates before microbial pressure is reduced risks:
5.2 Avoiding early nutrient loading
High nutrient introduction during high microbial pressure feeds harmful species.
This justifies delaying nutrient-intensive phases until Gate 4.
5.3 Avoiding simultaneous antimicrobials and binders
Binders reduce antimicrobial efficacy by adsorption.
Gates 2 and 3 are therefore separated.
5.4 Avoiding bile-stimulating agents early
Primary bile acids were already injurious.
Early stimulation would compound epithelial stress.
5.5 Context for gastric acid supplementation
HCl correction improves protein digestion and upstream control but does not replace the Gate stages.
It is managed as a parallel support noted in Chapter 3.
—
6. Preconditions for Entering Gate 1
Gate 1 begins only when:
Gate 0 confirms readiness for sequenced intervention.
—